|
|
Other links at Articles > Obstetrics and Gynecology |
| 2. |
Optimal Duration of Neoadjuvant Letrozole for Breast Cancer Unclear
|
|
|
Most postmenopausal breast cancer patients undergoing neoadjuvant treatment with the nonsteroidal aromatase inhibitor letrozole experience tumor volume reduction within 4 months, according to the findings of a phase IIb/III trial, but no optimal duration of therapy has yet been established. Reuters Health Information
|
| 4. |
Gum Disease and Elevated CRP Tied to Preeclampsia Risk
|
|
|
Periodontal disease and increased levels of C-reactive protein (CRP) in pregnant women heighten the risk of developing preeclampsia, researchers report in the April issue of the American Journal of Obstetrics and Gynecology. Reuters Health Information
|
|
|